SCHEMBL30795446

SCHEMBL30795446

Cc1cc(N2CCOCC2)nc(C2CC2)c1C(=O)NCc1ccc(Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
NAPEPLD Q6IQ20 3/20 0.47
THRB P10828 2/20 0.45
LMNA P02545 2/20 0.44
RXFP1 Q9HBX9 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TP53 P04637 1/20 0.43
KLKB1 P03952 1/20 0.43
KLK1 P06870 1/20 0.43
USP2 O75604 1/20 0.43
TSHR P16473 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
SCN2A Q99250 1/20 0.42
SCN10A Q9Y5Y9 1/20 0.42
PIK3CB P42338 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PIK3CA P42336 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2131268 1.00 KMT2A (0.51) KMT2AMEN1NAPEPLDTHRBLMNA
SCHEMBL30795212 0.91 TP53 (0.47) KMT2ANAPEPLDTHRBLMNAALDH1A1
SCHEMBL2129915 0.91 TP53 (0.47) KMT2ANAPEPLDTHRBLMNAALDH1A1
SCHEMBL2130581 0.89 PPARG (0.47) NAPEPLDTHRBLMNAALDH1A1TP53
SCHEMBL30794475 0.89 PPARG (0.47) NAPEPLDTHRBLMNAALDH1A1TP53
SCHEMBL30795136 0.88 NAPEPLD (0.49) NAPEPLDLMNAPIK3CA
SCHEMBL2130339 0.88 NAPEPLD (0.49) NAPEPLDLMNAPIK3CA
SCHEMBL30795710 0.87 KMT2A (0.48) KMT2AMEN1NAPEPLDLMNAALDH1A1
SCHEMBL2130365 0.87 KMT2A (0.48) KMT2AMEN1NAPEPLDLMNAALDH1A1
SCHEMBL30794831 0.86 MEN1 (0.45) KMT2AMEN1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed